$14.86
+0.07 (+0.47%)
Open$15.28
Previous Close$14.79
Day High$15.28
Day Low$14.45
52W High$27.40
52W Low$6.27
Volume—
Avg Volume26.9K
Market Cap132.63M
P/E Ratio—
EPS$-18.59
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+54.8% upside
Current
$14.86
$14.86
Target
$23.00
$23.00
$15.62
$23.00 avg
$28.09
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 3.59M | 3.48M | 3.01M |
| Net Income | 732.2K | 573.7K | 520.4K |
| Profit Margin | 20.4% | 16.5% | 17.3% |
| EBITDA | 1.09M | 1.00M | 849.7K |
| Free Cash Flow | 537.7K | 589.4K | 453.2K |
| Rev Growth | +3.4% | -1.6% | +9.6% |
| Debt/Equity | 0.28 | 0.26 | 0.25 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |